Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Last trade$29.22
Day change+$0.39 (+1.35%)
Day range$28.48 – $29.69
Volume1,591,465
Market cap$5.99B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SUPN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SUPN.
Recent news
Company coverage with links to the original publishers.
Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.
Supernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.
Biogen beat Q3 2026 earnings and revenue estimates with adjusted EPS of $2.62 and revenues of $2.80 billion. Growth drugs Skyclarys, Qalsody, Zurzuvae, and acquired Apellis products drove strong performance, with growth portfolio revenues rising ~50% year-over-year. However, legacy MS portfolio declined 13% and biosimilar sales fell 19%. The company tightened 2026 EPS guidance to $15.95-$16.75 while maintaining mid-single-digit revenue growth expectations.
Supernus Pharmaceuticals announced that the FDA has granted seven years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl), a subcutaneous infusion device for treating motor fluctuations in advanced Parkinson's disease patients. The exclusivity period began February 3, 2025. Additionally, the company submitted a supplemental New Drug Application for a second supplier with expected FDA approval by mid-2027.
Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 3, 2026
$8.13
Nov 6, 2026
special
Stock splits
Historical share-structure events and their execution dates.